Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer Center. TheCompany's first FDA cleared commercial product, RESONIC™, will use rapid pulses of acoustic shockwaves as an accessory to lasers for the removal of unwanted tattoos and the treatment of cellulite. The Company is based in Houston, Texas, and is actively engaged in bringing RESONIC to the market. The Company believes this "Soliton" method has the potential to lower tattoo removal costs for patients, while increasing profitability to practitioners, compared to current laser removal methods. The Company also believes the technology will provide the first non-invasive acoustic technology to target the underlying causes of dimples and ridges in cellulite. Soliton is investigating potential additional capabilities of the RAP technology. The device is currently cleared in the United States only for use in tattoo removal and cellulite.
Company profile
Ticker
SOLY
Exchange
Website
CEO
Bradley A. Hauser
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
364729076
SOLY stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
28 Dec 21
EFFECT
Notice of effectiveness
22 Dec 21
EFFECT
Notice of effectiveness
22 Dec 21
EFFECT
Notice of effectiveness
21 Dec 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Dec 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Dec 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Dec 21
POS AM
Prospectus update (post-effective amendment)
16 Dec 21
POS AM
Prospectus update (post-effective amendment)
16 Dec 21
POS AM
Prospectus update (post-effective amendment)
16 Dec 21
Latest ownership filings
SC 13D/A
Remeditex Ventures LLC
20 Dec 21
4
JOE D TANNER
17 Dec 21
4
Change in insider ownership
17 Dec 21
4
WALTER V KLEMP
17 Dec 21
4
Michael S. Kaminer
17 Dec 21
4
Niquette L. Hunt
17 Dec 21
4
Bradley Hauser
17 Dec 21
4
Danika R Harrison
17 Dec 21
4
Jonathan P. Foster
17 Dec 21
4
Christopher Capelli
17 Dec 21
Financial summary
Quarter (USD) | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 21.95 mm | 21.95 mm | 21.95 mm | 21.95 mm | 21.95 mm | 21.95 mm |
Cash burn (monthly) | (no burn) | 1.07 mm | 2.10 mm | 2.00 mm | 1.49 mm | 1.42 mm |
Cash used (since last report) | n/a | 33.16 mm | 64.82 mm | 61.93 mm | 46.10 mm | 43.96 mm |
Cash remaining | n/a | -11.21 mm | -42.87 mm | -39.98 mm | -24.16 mm | -22.01 mm |
Runway (months of cash) | n/a | -10.4 | -20.4 | -20.0 | -16.2 | -15.5 |
Institutional ownership, Q4 2021
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 76 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 400.00 |
Total calls | 12.00 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Simplex Trading | 0.00 | $0.00 |
Remeditex Ventures | 0.00 | $0.00 |